HIMS & Hers Reports Largest Single-Day Share Collapse in Three Months as Strategic Shift to Branded GLP-1 Drugs Triggers Revenue Miss and Restructuring Charges
HIMS & Hers Health, the direct-to-consumer telehealth platform, experienced its steepest single-session stock decline in three months after reporting first-quarter results that fell short of Wall Street expectations, signaling growing pressure on the company's transition strategy away from compounded GLP-1 weight-loss medications toward branded drugs supplied by Novo Nordisk and Eli Lilly. The earnings miss—revenue of $608 million against a $617.5 million Bloomberg consensus estimate—coincided with a sharp swing into loss territory, raising questions about the near-term financial viability of the platform's flagship repositioning.
The company recorded $33.5 million in restructuring charges during the quarter, encompassing inventory write-downs and transition costs directly tied to the pivot. Despite the miss, CEO Andrew Dudum defended the shift on the earnings call, characterizing the move as strategically necessary and noting that adoption and demand for weight-loss treatments remain near record levels, even outpacing the surge observed following the company's New Year's and Super Bowl marketing campaigns. The discrepancy between management's optimism and market reaction highlights investor skepticism regarding the timeline and profitability of the branded GLP-1 transition.
The quarterly loss of 40 cents per share compares sharply with the 20-cent profit recorded in the same period a year earlier, reflecting both the operational costs of the pivot and intensifying competition in the telehealth weight-loss segment. The restructuring charges suggest significant inventory and supply-chain adjustments as HIMS repositions itself within a rapidly evolving regulatory and market landscape for obesity treatments. Analysts will scrutinize subsequent quarters for evidence that the strategic shift translates into sustainable revenue growth or whether the transition costs continue to weigh on earnings. HIMS shares were indicated sharply lower in premarket trading following the release.